scholarly journals Altered membrane properties and firing patterns of external globus pallidus neurons in the R6/2 mouse model of Huntington's disease

2016 ◽  
Vol 94 (12) ◽  
pp. 1400-1410 ◽  
Author(s):  
Garnik Akopian ◽  
Joshua Barry ◽  
Carlos Cepeda ◽  
Michael S. Levine
2015 ◽  
Vol 113 (7) ◽  
pp. 2953-2966 ◽  
Author(s):  
Tim Indersmitten ◽  
Conny H. Tran ◽  
Carlos Cepeda ◽  
Michael S. Levine

The Q175 knockin mouse model of Huntington's disease (HD) carries a CAG trinucleotide expansion of the human mutant huntingtin allele in its native mouse genomic context and recapitulates the genotype more closely than transgenic models. In this study we examined the progression of changes in intrinsic membrane properties and excitatory and inhibitory synaptic transmission, using whole cell patch-clamp recordings of medium-sized spiny neurons (MSNs) in the dorsolateral striatum and cortical pyramidal neurons (CPNs) in layers 2/3 of the primary motor cortex in brain slices from heterozygous (Q175+/−) and homozygous (Q175+/+) mice. Input resistance in MSNs from Q175+/+ and Q175+/− mice was significantly increased compared with wild-type (WT) littermates beginning at 2 mo. Furthermore, the frequency of spontaneous and miniature excitatory postsynaptic currents (EPSCs) was significantly reduced in MSNs from Q175+/+ and Q175+/− mice compared with WTs beginning at 7 mo. In contrast, the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) and IPSC-to-EPSC ratios were increased in MSNs from Q175+/+ mice beginning at 2 mo. Morphologically, significant decreases in spine density of MSNs from Q175+/− and Q175+/+ mice occurred at 7 and 12 mo. In CPNs, sIPSC frequencies and IPSC-to-EPSC ratios were significantly increased in Q175+/− mice compared with WTs at 12 mo. There were no changes in intrinsic membrane properties or morphology. In summary, we show a number of alterations in electrophysiological and morphological properties of MSNs in Q175 mice that are similar to other HD mouse models. However, unlike other models, CPN inhibitory activity is increased in Q175+/− mice, indicating reduced cortical excitability.


Neuroscience ◽  
2016 ◽  
Vol 329 ◽  
pp. 363-379 ◽  
Author(s):  
Zhuowei Du ◽  
Marine Chazalon ◽  
Emma Bestaven ◽  
Thierry Leste-Lasserre ◽  
Jérôme Baufreton ◽  
...  

2021 ◽  
Author(s):  
Danielle A. Simmons ◽  
Brian D. Mills ◽  
Robert R. Butler III ◽  
Jason Kuan ◽  
Tyne L. M. McHugh ◽  
...  

AbstractHuntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomarkers. Multi-modal magnetic resonance imaging (MRI) and plasma cytokines have been suggested as disease onset/progression biomarkers, but their ability to detect treatment efficacy is understudied. This study used the R6/2 mouse model of HD to assess if structural neuroimaging and biofluid assays can detect treatment response using as a prototype the small molecule p75NTR ligand LM11A-31, shown previously to reduce HD phenotypes in these mice. LM11A-31 alleviated volume reductions in multiple brain regions, including striatum, of vehicle-treated R6/2 mice relative to wild-types (WTs), as assessed with in vivo MRI. LM11A-31 also normalized changes in diffusion tensor imaging (DTI) metrics and diminished increases in certain plasma cytokine levels, including tumor necrosis factor-alpha and interleukin-6, in R6/2 mice. Finally, R6/2-vehicle mice had increased urinary levels of the p75NTR extracellular domain (ecd), a cleavage product released with pro-apoptotic ligand binding that detects the progression of other neurodegenerative diseases; LM11A-31 reduced this increase. These results are the first to show that urinary p75NTR-ecd levels are elevated in an HD mouse model and can be used to detect therapeutic effects. These data also indicate that multi-modal MRI and plasma cytokine levels may be effective pharmacodynamic biomarkers and that using combinations of these markers would be a viable and powerful option for clinical trials.


2015 ◽  
Vol 44 ◽  
pp. 121-127 ◽  
Author(s):  
Kuo-Hsuan Chang ◽  
Yih-Ru Wu ◽  
Yi-Chun Chen ◽  
Chiung-Mei Chen

2006 ◽  
Vol 5 (3) ◽  
pp. 483-492 ◽  
Author(s):  
Tsz M. Tsang ◽  
Ben Woodman ◽  
Gerard A. Mcloughlin ◽  
Julian L. Griffin ◽  
Sarah J. Tabrizi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document